1. Serum glial fibrillary acidic protein indicates memory impairment in patients with chronic heart failure
- Author
-
Jan Traub, Markus Otto, Roxane Sell, György A. Homola, Petra Steinacker, Patrick Oeckl, Caroline Morbach, Stefan Frantz, Mirko Pham, Stefan Störk, Guido Stoll, and Anna Frey
- Subjects
Glial fibrillary acidic protein ,GFAP ,Chronic heart failure ,Cognitive decline ,Memory dysfunction ,Brain atrophy ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Aims Cognitive dysfunction occurs frequently in patients with heart failure (HF), but early detection remains challenging. Serum glial fibrillary acidic protein (GFAP) is an emerging biomarker of cognitive decline in disorders of primary neurodegeneration such as Alzheimer's disease. We evaluated the utility of serum GFAP as a biomarker for cognitive dysfunction and structural brain damage in patients with stable chronic HF. Methods and results Using bead‐based single molecule immunoassays, we quantified serum levels of GFAP in patients with HF participating in the prospective Cognition.Matters‐HF study. Participants were extensively phenotyped, including cognitive testing of five separate domains and magnetic resonance imaging (MRI) of the brain. Univariable and multivariable models, also accounting for multiple testing, were run. One hundred and forty‐six chronic HF patients with a mean age of 63.8 ± 10.8 years were included (15.1% women). Serum GFAP levels (median 246 pg/mL, quartiles 165, 384 pg/mL; range 66 to 1512 pg/mL) did not differ between sexes. In the multivariable adjusted model, independent predictors of GFAP levels were age (T = 5.5; P
- Published
- 2022
- Full Text
- View/download PDF